Lifecore Short Long Term Debt Total from 2010 to 2025

LFCR Stock   6.83  0.23  3.48%   
Lifecore Biomedical Short and Long Term Debt Total yearly trend continues to be relatively stable with very little volatility. Short and Long Term Debt Total is likely to grow to about 157.4 M this year. During the period from 2010 to 2025, Lifecore Biomedical Short and Long Term Debt Total destribution of quarterly values had range of 220.9 M from its regression line and mean deviation of  60,590,106. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
1996-02-29
Previous Quarter
136.9 M
Current Value
131.3 M
Quarterly Volatility
64 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 21.8 M or Total Revenue of 140.1 M, as well as many indicators such as Price To Sales Ratio of 0.2, Dividend Yield of 0.0 or PTB Ratio of 0.74. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.
  
Check out the analysis of Lifecore Biomedical Correlation against competitors.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Latest Lifecore Biomedical's Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Lifecore Biomedical over the last few years. It is Lifecore Biomedical's Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Lifecore Short Long Term Debt Total Regression Statistics

Arithmetic Mean106,784,606
Geometric Mean68,781,296
Coefficient Of Variation64.15
Mean Deviation60,590,106
Median130,360,000
Standard Deviation68,497,779
Sample Variance4691.9T
Range220.9M
R-Value0.79
Mean Square Error1910.1T
R-Squared0.62
Significance0.0003
Slope11,328,970
Total Sum of Squares70379.2T

Lifecore Short Long Term Debt Total History

2025157.4 M
2024149.9 M
2023130.4 M
2022153.1 M
2021153.2 M
2020221.4 M
2019221.1 M

About Lifecore Biomedical Financial Statements

Lifecore Biomedical shareholders use historical fundamental indicators, such as Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lifecore Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Short and Long Term Debt Total149.9 M157.4 M

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.